Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-53817 and AL-78843 in Allergic Conjunctivitis
NCT02079649Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of olopatadine and naphazoline in allergic conjunctivitis (AC) (4 arms), sponsored by Alcon Inc. Primary endpoint: Mean Change From Baseline in Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)]. Started Apr 2014; status: completed.
02
Drugs
olopatadinenaphazoline
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT02079649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079649.